Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism

Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention of venous thromboembolism (VTE) compared with low molecular weight heparin (LMWH)/warfarin and other new oral anticoagulants (NOACs). Material and methods. Cost-effectiveness analysis was performed using a Ma...

Full description

Bibliographic Details
Main Author: A. V. Rudakova
Format: Article
Language:English
Published: Столичная издательская компания 2015-11-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/323